Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 9/20 | 0.66 |
| ▸ | CMA1 | P23946 | 3/20 | 0.66 |
| ▸ | MASP2 | O00187 | 1/20 | 0.60 |
| ▸ | ACP3 | P15309 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4162691 | 0.85 | CTSG (0.71) | CTSGCMA1MASP2ACP3DRD4 | |
| SCHEMBL2748880 | 0.82 | CTSG (0.65) | CTSGCMA1MASP2ACP3 | |
| SCHEMBL1614578 | 0.81 | CTSG (0.76) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL1589329 | 0.81 | CTSG (0.57) | CTSGCMA1MASP2ACP3DRD4 | |
| SCHEMBL1614368 | 0.80 | CTSG (0.63) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL31211679 | 0.80 | CTSG (0.68) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL1613656 | 0.80 | CTSG (0.68) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL23752427 | 0.80 | CTSG (0.82) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL1614713 | 0.80 | CTSG (0.62) | CTSGCMA1MASP2ACP3NPC1 | |
| SCHEMBL1260969 | 0.79 | CTSG (1.00) | CTSGCMA1MASP2ACP3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497373-B2 | Phosphonic acid compounds as inhibitors of serine proteases | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120238528-A1 | NOVEL PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | GRECO MICHAEL N (US) | 2012-09-20 | — | — | US | disclosed |
| US-8207338-B2 | Phosphonic acid compounds as inhibitors of serine proteases | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8198440-B2 | Phosphonic acid compounds as inhibitors of serine proteases | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2012-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238528-A1 | NOVEL PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | HPN, PRSS1, SERPINB1 | CTSG 251/4885CMA1 137/4885MASP2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.